Viz.ai, a pioneering AI-driven healthcare technology company focused on disease detection and intelligent care coordination, has recently inked an exclusive licensing agreement with the University of California, San Francisco (UCSF) to facilitate the commercialization of three advanced AI algorithms designed for the automated detection of cardiovascular diseases.
These cutting-edge AI algorithms, meticulously crafted by prominent researchers at UCSF, have been devised to identify cardiac amyloidosis, pulmonary hypertension, and supraventricular tachycardia. These breakthrough algorithms rely on the analysis of electrocardiograms (ECGs), the most widely employed diagnostic test for assessing the cardiac structure and electrical activity of the heart.
Upon receiving regulatory clearance, these three innovative algorithms will be seamlessly integrated into Viz.ai's growing portfolio of healthcare solutions. This portfolio already encompasses ECG-based AI algorithms, ECG viewers, AI-driven interpretation of echocardiograms (echos), and echo viewers. By leveraging these technologies, cardiac care teams will be empowered to detect diseases at earlier stages and orchestrate real-time care coordination efforts.
Click here to read the original news story.